Beijing Med-Pharm, Shanghai Novartis Ink Enablex Agreement

Beijing Med-Pharm and Novartis’ subsidiary Shanghai Novartis Trading have entered an exclusive agreement to register, market and distribute Enablex in China.

Enablex (darifenacin) is a treatment of urinary incontinence, urgency and urinary frequency related to an overactive bladder (OAB). Global annual sales of OAB medication is approximately $2.25 billion, according to Beijing Med-Pharm.

Under the terms of the agreement, Beijing Med-Pharm will be responsible for obtaining regulatory approval of Enablex. Once approved, Beijing Med-Pharm will have the exclusive rights to sell, market and distribute Enablex in China for 10 years.